The Netherlands: Forbion SPAC and enGene to merge and list on Nasdaq

Nasdaq listed Forbion European Acquisition Corp (FEAC), the Forbion SPAC, and enGene, a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues, have entered into a business combination agreement that will result in the combined company being listed on Nasdaq. The company will be named enGene Holdings. Financing for the…

You must be a HMI Subscriber to view this content.

Subscribe Now »